1
|
Wang X, Cornish AE, Do MH, Brunner JS, Hsu TW, Xu Z, Malik I, Edwards C, Capistrano KJ, Zhang X, Ginsberg MH, Finley LWS, Lim MS, Horwitz SM, Li MO. Onco-Circuit Addiction and Onco-Nutrient mTORC1 Signaling Vulnerability in a Model of Aggressive T Cell Malignancy. bioRxiv 2024:2024.04.03.587917. [PMID: 38617314 PMCID: PMC11014592 DOI: 10.1101/2024.04.03.587917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/16/2024]
Abstract
How genetic lesions drive cell transformation and whether they can be circumvented without compromising function of non-transformed cells are enduring questions in oncology. Here we show that in mature T cells-in which physiologic clonal proliferation is a cardinal feature- constitutive MYC transcription and Tsc1 loss in mice modeled aggressive human malignancy by reinforcing each other's oncogenic programs. This cooperation was supported by MYC-induced large neutral amino acid transporter chaperone SLC3A2 and dietary leucine, which in synergy with Tsc1 deletion overstimulated mTORC1 to promote mitochondrial fitness and MYC protein overexpression in a positive feedback circuit. A low leucine diet was therapeutic even in late-stage disease but did not hinder T cell immunity to infectious challenge, nor impede T cell transformation driven by constitutive nutrient mTORC1 signaling via Depdc5 loss. Thus, mTORC1 signaling hypersensitivity to leucine as an onco-nutrient enables an onco-circuit, decoupling pathologic from physiologic utilization of nutrient acquisition pathways.
Collapse
|
2
|
Day TC, Malik I, Boateng S, Hauschild KM, Lerner MD. Vocal Emotion Recognition in Autism: Behavioral Performance and Event-Related Potential (ERP) Response. J Autism Dev Disord 2024; 54:1235-1248. [PMID: 36694007 DOI: 10.1007/s10803-023-05898-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/10/2023] [Indexed: 01/25/2023]
Abstract
Autistic youth display difficulties in emotion recognition, yet little research has examined behavioral and neural indices of vocal emotion recognition (VER). The current study examines behavioral and event-related potential (N100, P200, Late Positive Potential [LPP]) indices of VER in autistic and non-autistic youth. Participants (N = 164) completed an emotion recognition task, the Diagnostic Analyses of Nonverbal Accuracy (DANVA-2) which included VER, during EEG recording. The LPP amplitude was larger in response to high intensity VER, and social cognition predicted VER errors. Verbal IQ, not autism, was related to VER errors. An interaction between VER intensity and social communication impairments revealed these impairments were related to larger LPP amplitudes during low intensity VER. Taken together, differences in VER may be due to higher order cognitive processes, not basic, early perception (N100, P200), and verbal cognitive abilities may underlie behavioral, yet occlude neural, differences in VER processing.
Collapse
Affiliation(s)
- Talena C Day
- Psychology Department, Stony Brook University, Stony Brook, Psychology B-354, Stony Brook, NY, 11794-2500, USA
| | - Isha Malik
- Psychology Department, Stony Brook University, Stony Brook, Psychology B-354, Stony Brook, NY, 11794-2500, USA
| | - Sydney Boateng
- Psychology Department, Stony Brook University, Stony Brook, Psychology B-354, Stony Brook, NY, 11794-2500, USA
| | | | - Matthew D Lerner
- Psychology Department, Stony Brook University, Stony Brook, Psychology B-354, Stony Brook, NY, 11794-2500, USA.
| |
Collapse
|
3
|
Do MH, Shi W, Ji L, Ladewig E, Zhang X, Srivastava RM, Capistrano KJ, Edwards C, Malik I, Nixon BG, Stamatiades EG, Liu M, Li S, Li P, Chou C, Xu K, Hsu TW, Wang X, Chan TA, Leslie CS, Li MO. Reprogramming tumor-associated macrophages to outcompete endovascular endothelial progenitor cells and suppress tumor neoangiogenesis. Immunity 2023; 56:2555-2569.e5. [PMID: 37967531 DOI: 10.1016/j.immuni.2023.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2023] [Revised: 07/03/2023] [Accepted: 10/18/2023] [Indexed: 11/17/2023]
Abstract
Tumors develop by invoking a supportive environment characterized by aberrant angiogenesis and infiltration of tumor-associated macrophages (TAMs). In a transgenic model of breast cancer, we found that TAMs localized to the tumor parenchyma and were smaller than mammary tissue macrophages. TAMs had low activity of the metabolic regulator mammalian/mechanistic target of rapamycin complex 1 (mTORC1), and depletion of negative regulator of mTORC1 signaling, tuberous sclerosis complex 1 (TSC1), in TAMs inhibited tumor growth in a manner independent of adaptive lymphocytes. Whereas wild-type TAMs exhibited inflammatory and angiogenic gene expression profiles, TSC1-deficient TAMs had a pro-resolving phenotype. TSC1-deficient TAMs relocated to a perivascular niche, depleted protein C receptor (PROCR)-expressing endovascular endothelial progenitor cells, and rectified the hyperpermeable blood vasculature, causing tumor tissue hypoxia and cancer cell death. TSC1-deficient TAMs were metabolically active and effectively eliminated PROCR-expressing endothelial cells in cell competition experiments. Thus, TAMs exhibit a TSC1-dependent mTORC1-low state, and increasing mTORC1 signaling promotes a pro-resolving state that suppresses tumor growth, defining an innate immune tumor suppression pathway that may be exploited for cancer immunotherapy.
Collapse
Affiliation(s)
- Mytrang H Do
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA
| | - Wei Shi
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Liangliang Ji
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Erik Ladewig
- Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Xian Zhang
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Raghvendra M Srivastava
- Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Kristelle J Capistrano
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Chaucie Edwards
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Isha Malik
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Briana G Nixon
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA
| | - Efstathios G Stamatiades
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Ming Liu
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Shun Li
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Peng Li
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Chun Chou
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Ke Xu
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA
| | - Ting-Wei Hsu
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Graduate Program in Biochemistry and Structural Biology, Cell and Developmental Biology, and Molecular Biology, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA
| | - Xinxin Wang
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA
| | - Timothy A Chan
- Immunogenomics & Precision Oncology Platform (IPOP), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Christina S Leslie
- Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Ming O Li
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA.
| |
Collapse
|
4
|
Zhang X, Li S, Malik I, Do MH, Ji L, Chou C, Shi W, Capistrano KJ, Zhang J, Hsu TW, Nixon BG, Xu K, Wang X, Ballabio A, Schmidt LS, Linehan WM, Li MO. Reprogramming tumour-associated macrophages to outcompete cancer cells. Nature 2023; 619:616-623. [PMID: 37380769 PMCID: PMC10719927 DOI: 10.1038/s41586-023-06256-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 05/24/2023] [Indexed: 06/30/2023]
Abstract
In metazoan organisms, cell competition acts as a quality control mechanism to eliminate unfit cells in favour of their more robust neighbours1,2. This mechanism has the potential to be maladapted, promoting the selection of aggressive cancer cells3-6. Tumours are metabolically active and are populated by stroma cells7,8, but how environmental factors affect cancer cell competition remains largely unknown. Here we show that tumour-associated macrophages (TAMs) can be dietarily or genetically reprogrammed to outcompete MYC-overexpressing cancer cells. In a mouse model of breast cancer, MYC overexpression resulted in an mTORC1-dependent 'winner' cancer cell state. A low-protein diet inhibited mTORC1 signalling in cancer cells and reduced tumour growth, owing unexpectedly to activation of the transcription factors TFEB and TFE3 and mTORC1 in TAMs. Diet-derived cytosolic amino acids are sensed by Rag GTPases through the GTPase-activating proteins GATOR1 and FLCN to control Rag GTPase effectors including TFEB and TFE39-14. Depletion of GATOR1 in TAMs suppressed the activation of TFEB, TFE3 and mTORC1 under the low-protein diet condition, causing accelerated tumour growth; conversely, depletion of FLCN or Rag GTPases in TAMs activated TFEB, TFE3 and mTORC1 under the normal protein diet condition, causing decelerated tumour growth. Furthermore, mTORC1 hyperactivation in TAMs and cancer cells and their competitive fitness were dependent on the endolysosomal engulfment regulator PIKfyve. Thus, noncanonical engulfment-mediated Rag GTPase-independent mTORC1 signalling in TAMs controls competition between TAMs and cancer cells, which defines a novel innate immune tumour suppression pathway that could be targeted for cancer therapy.
Collapse
Affiliation(s)
- Xian Zhang
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Shun Li
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Isha Malik
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Mytrang H Do
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA
| | - Liangliang Ji
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Chun Chou
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Wei Shi
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Kristelle J Capistrano
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Jing Zhang
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Ting-Wei Hsu
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Graduate Program in Biochemistry and Structural Biology, Cell and Developmental Biology, and Molecular Biology, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA
| | - Briana G Nixon
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA
| | - Ke Xu
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA
- META Pharmaceuticals, Shenzhen, China
| | - Xinxin Wang
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA
| | - Andrea Ballabio
- Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy
- Medical Genetics Unit, Department of Medical and Translational Science, Federico II University, Naples, Italy
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
- Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA
| | - Laura S Schmidt
- Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA
- Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - W Marston Linehan
- Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA
| | - Ming O Li
- Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA.
| |
Collapse
|
5
|
Perros P, Basu A, Boelaert K, Dayan C, Vaidya B, Williams GR, Lazarus JH, Hickey J, Drake WM, Crown A, Orme SM, Johnson A, Ray DW, Leese GP, Jones TH, Abraham P, Grossman A, Rees A, Razvi S, Gibb FW, Moran C, Madathil A, Žarković MP, Plummer Z, Jarvis S, Falinska A, Velusamy A, Sanderson V, Pariani N, Atkin SL, Syed AA, Sathyapalan T, Nag S, Gilbert J, Gleeson H, Levy MJ, Johnston C, Sturrock N, Bennett S, Mishra B, Malik I, Karavitaki N. Postradioiodine Graves' management: The PRAGMA study. Clin Endocrinol (Oxf) 2022; 97:664-675. [PMID: 35274331 DOI: 10.1111/cen.14719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Revised: 01/04/2022] [Accepted: 01/05/2022] [Indexed: 11/29/2022]
Abstract
OBJECTIVE Thyroid status in the months following radioiodine (RI) treatment for Graves' disease can be unstable. Our objective was to quantify frequency of abnormal thyroid function post-RI and compare effectiveness of common management strategies. DESIGN Retrospective, multicentre and observational study. PATIENTS Adult patients with Graves' disease treated with RI with 12 months' follow-up. MEASUREMENTS Euthyroidism was defined as both serum thyrotropin (thyroid-stimulating hormone [TSH]) and free thyroxine (FT4) within their reference ranges or, when only one was available, it was within its reference range; hypothyroidism as TSH ≥ 10 mU/L, or subnormal FT4 regardless of TSH; hyperthyroidism as TSH below and FT4 above their reference ranges; dysthyroidism as the sum of hypo- and hyperthyroidism; subclinical hypothyroidism as normal FT4 and TSH between the upper limit of normal and <10 mU/L; and subclinical hyperthyroidism as low TSH and normal FT4. RESULTS Of 812 patients studied post-RI, hypothyroidism occurred in 80.7% and hyperthyroidism in 48.6% of patients. Three principal post-RI management strategies were employed: (a) antithyroid drugs alone, (b) levothyroxine alone, and (c) combination of the two. Differences among these were small. Adherence to national guidelines regarding monitoring thyroid function in the first 6 months was low (21.4%-28.7%). No negative outcomes (new-onset/exacerbation of Graves' orbitopathy, weight gain, and cardiovascular events) were associated with dysthyroidism. There were significant differences in demographics, clinical practice, and thyroid status postradioiodine between centres. CONCLUSIONS Dysthyroidism in the 12 months post-RI was common. Differences between post-RI strategies were small, suggesting these interventions alone are unlikely to address the high frequency of dysthyroidism.
Collapse
Affiliation(s)
- Petros Perros
- Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
| | - Ansu Basu
- Department of Endocrinology and Diabetes, Sandwell and West Birmingham Hospitals, Birmingham, UK
| | - Kristien Boelaert
- Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
| | - Colin Dayan
- Thyroid Research Group, Institute of Molecular Medicine, Cardiff University School of Medicine, Cardiff, UK
| | - Bijay Vaidya
- Department of Endocrinology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK
| | - Graham R Williams
- Molecular Endocrinology Laboratory, Imperial College London, London, UK
| | - John H Lazarus
- Thyroid Research Group, Institute of Molecular Medicine, Cardiff University School of Medicine, Cardiff, UK
| | | | - William M Drake
- Department of Endocrinology, St Bartholomews Hospital, London, UK
| | - Anna Crown
- Department of Endocrinology, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK
| | - Stephen M Orme
- Department of Endocrinology, St. James's University Hospital, Leeds, UK
| | - Andrew Johnson
- Department of Endocrinology and Diabetes, North Bristol NHS Trust, Bristol, UK
| | - David W Ray
- Manchester Centre for Endocrinology and Diabetes, Institute of Human Development, The University of Manchester, Manchester, UK
| | - Graham P Leese
- Department of Endocrinology and Diabetes, Ninewells Hospital and Medical School, Dundee, UK
| | - Thomas Hugh Jones
- Centre for Diabetes and Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, UK
| | - Prakash Abraham
- Department of Diabetes and Endocrinology, Aberdeen Royal Infirmary, Aberdeen, UK
| | - Ashley Grossman
- Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
| | - Aled Rees
- School of Medicine, Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK
| | - Salman Razvi
- Department of Endocrinology, Gateshead Health NHS Foundation Trust, Gateshead, UK
| | - Fraser W Gibb
- Edinburgh Centre for Endocrinology and Diabetes, Edinburgh, UK
| | - Carla Moran
- Addenbrooke's Hospital, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge Metabolic Research Laboratories, Cambridge, UK
| | - Asgar Madathil
- Department of Endocrinology and Metabolic Medicine, Northumbria Healthcare NHS Foundation Trust, Northumberland, UK
| | - Miloš P Žarković
- Serbia Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | | | - Sheba Jarvis
- Molecular Endocrinology Laboratory, Imperial College London, London, UK
| | | | - Anand Velusamy
- Department of Endocrinology, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK
| | - Violet Sanderson
- Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
| | - Nadia Pariani
- Addenbrooke's Hospital, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge Metabolic Research Laboratories, Cambridge, UK
| | - Stephen L Atkin
- Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK
| | - Akheel A Syed
- Department of Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK
| | | | - Sath Nag
- Department of Endocrinology, The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK
| | - Jackie Gilbert
- Department of Endocrinology, King's College Hospital, London, UK
| | - Helena Gleeson
- Department of Endocrinology, University Hospitals of Leicester, Leicester, UK
| | - Miles J Levy
- Department of Endocrinology, University Hospitals of Leicester, Leicester, UK
| | - Colin Johnston
- Department of Endocrinology and Diabetes, West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK
| | - Nigel Sturrock
- Department of Endocrinology and Metabolic Medicine, Nottingham City Hospitals NHS Trust, Nottingham, UK
| | - Stuart Bennett
- Department of Endocrinology and Metabolic Medicine, Northumbria Healthcare NHS Foundation Trust, Northumberland, UK
| | - Biswa Mishra
- Department of Endocrinology and Metabolic Medicine, Pennine Acute Hospitals NHS Trust, Royal Oldham Hospital, Oldham, UK
| | - Isha Malik
- Department of Endocrinology and Metabolic Medicine, Pennine Acute Hospitals NHS Trust, Royal Oldham Hospital, Oldham, UK
| | - Niki Karavitaki
- Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
| |
Collapse
|
6
|
Hartley A, Hammond-Haley M, Marshall DC, Salciccioli JD, Malik I, Khamis RY, Shalhoub J. Trends in mortality from aortic stenosis in Europe: 2000–2017. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Trends in mortality from aortic stenosis across Europe are not well understood, especially given the significant growth in transcatheter aortic valve replacement (TAVR) in the last 10 years.
Purpose
To describe trends in mortality from aortic stenosis in European countries from 2000 to 2017.
Methods
Age-standardised death rates were extracted from the World Health Organisation Mortality Database, using the International Classification of Diseases 10th edition code for non-rheumatic aortic stenosis for those aged >45 years between 2000 and 2017. The UK and countries from the European Union with at least 1,000,000 inhabitants and at least 50% available datapoints over the study period were included: a total of 23 countries. Trends were described using Joinpoint regression analysis.
Results
No reductions in mortality were demonstrated across all countries 2000–2017 (Figure 1). Large increases in mortality were found for Croatia, Poland and Slovakia for both sexes (>300% change). Mortality plateaued in Germany from 2008 in females and 2012 in males, whilst mortality in the Netherlands declined for both sexes from 2007. Mortality differences between the sexes were observed, with greater mortality for males than females across most countries.
Conclusions
Mortality from aortic stenosis has increased across Europe from 2000 to 2017. There are, however, sizable differences in mortality trends between Eastern and Western European countries. Significant plateauing or declining mortality was observed for recent years in countries with greater access to TAVR, whilst increasing trends were observed in countries with the least TAVR use. The need for health resource planning strategies to specifically target AS, particularly given the expected increase with aging populations, is highlighted.
Funding Acknowledgement
Type of funding sources: None. Figure 1. Joinpoint regression analysis for trends in age-standardised death rates from non-rheumatic aortic stenosis for those aged >45 years in Europe from 2000 to 2017. Clear squares indicate males; filled circles indicate females. The lines (dotted for males, solid for females) represent modelled trends based on joinpoint data.
Collapse
Affiliation(s)
- A Hartley
- Imperial College London, London, United Kingdom
| | | | | | - J D Salciccioli
- Brigham and Women'S Hospital, Harvard Medical School, Boston, United States of America
| | - I Malik
- Imperial College London, London, United Kingdom
| | - R Y Khamis
- Imperial College London, London, United Kingdom
| | - J Shalhoub
- Imperial College London, London, United Kingdom
| |
Collapse
|
7
|
Panoulas V, Rathod K, Kain A, Firoozi S, Nevett J, Kalra S, Malik I, Mathur A, Redwood S, MacCarthy P, Wragg A, Jones D, Dalby M. Impact of early (<24h) versus delayed (>24h) intervention in patients with non ST segment elevation myocardial infarction (an observational study of 20882 patients). Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
In patients presenting with non ST-segment elevation acute coronary syndromes (NSTE-ACS) an invasive approach has been shown to be superior to conservative management.
Purpose
We aimed to investigate the optimal timing of invasive coronary angiography and subsequent intervention.
Methods
We examined the impact ofearly (≤24h) versus delayed (>24h) intervention in a large observational cohort of 20882 consecutive patients with acute NSTE myocardial infarction (NSTEMI) treated with PCI between 2005 and 2015 at 9 tertiary cardiac centers in London (UK) using Cox-regression analysis and propensity matching.
Results
Mean age was 64.5±12.7 years and 26.1% were females. A quarter (27.6%), were treated within 24h.Patients treated within 24h were slightly younger (62.8±12.8 vs. 65.2±12.6, p<0.001), most commonly male (76% vs. 72.9%, p<0.001) and were more frequently ventilated (2.3% vs. 1.4%, p<0.001) and in cardiogenic shock (3.6% vs. 1.4%, p<0.001) with dynamic changes on their ECG (84.5% vs. 76.1% p<0.001). At a median follow up of 4.2 years (interquartile range 1.8 to 7) 17.7% of patients had died. Estimated 5-year survival in patients treated within 24h was 84.6% vs. 81% for those treated >24h following their presentation (p<0.001). This survival benefit remained following adjustment for confounders; HR (delayed vs. early management)1.11 (95% CI 1.003 to 1.23, p=0.046). In the propensity matched cohort of 4356 patients in each group, there remained a trend for higher survival in the early intervention group (p=0.061).
Conclusions
Notwithstanding the limitations of the retrospective design, this real-world cohort of NSTEMI patients suggests that an early intervention (≤24h) may improve mid term survival.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- V Panoulas
- Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom
| | - K Rathod
- Barts Health NHS Trust, Cardiology, London, United Kingdom
| | - A Kain
- Barts Health NHS Trust, Cardiology, London, United Kingdom
| | - S Firoozi
- St George's Healthcare NHS Trust, Cardiology, London, United Kingdom
| | - J Nevett
- London Ambulance Service, London, United Kingdom
| | - S Kalra
- Royal Free Hospital, Cardiology, London, United Kingdom
| | - I Malik
- Hammersmith Hospital, London, United Kingdom
| | - A Mathur
- Barts Health NHS Trust, Cardiology, London, United Kingdom
| | - S Redwood
- St Thomas' Hospital, Cardiology, London, United Kingdom
| | - P.A MacCarthy
- King's College Hospital, Cardiology, London, United Kingdom
| | - A Wragg
- Barts Health NHS Trust, Cardiology, London, United Kingdom
| | - D Jones
- Barts Health NHS Trust, Cardiology, London, United Kingdom
| | - M.C Dalby
- Harefield Hospital, Interventional cardiology, London, United Kingdom
| |
Collapse
|
8
|
Arri S, Myat A, Malik I, Curzen N, Baumbach A, Gunning M, Henderson R, Ludman P, Banning A, Blackman D, Densem C, Stables R, Byrne J, Hildick-Smith D, Redwood S. New onset left bundle branch block after transcatheter aortic valve implantation and the effect on long-term survival – a UK wide experience. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
New onset left bundle branch block (LBBB) is the most common conduction disturbance associated with transcatheter aortic valve implantation (TAVI). It has been shown to adversely affect cardiac function and increase re-hospitalisation, although its impact on mortality remains contentious.
Methods
We conducted an observational cohort analysis of all TAVI procedures performed by 13 heart teams in the United Kingdom from inception of their structural programmes until 31st July 2013. The primary outcome was 1-year all-cause mortality. Secondary outcomes included left ventricular ejection fraction (LVEF) at 30 days and need for a post-TAVI permanent pacemaker (PPM).
Results
1785 patients were eligible for inclusion to the study. The primary analysis cohort was composed of 1409 patients with complete electrocardiographic (ECG) data pre- and post-TAVI. Pre-existing LBBB was present in 200 (14.2%) patients. New LBBB occurred in 323 (22.9%) patients post TAVI, which resolved in 99 (7%) patients prior to discharge. A balloon-expandable device was implanted in 968 (69%) patients, whilst 421 (30%) patients received a self-expandable valve. New LBBB was observed in 120 (12.4%) and 192 (45.6%) patients receiving a balloon- or self-expandable prosthesis respectively.
Overall 1-year all-cause mortality post TAVI was 18.7%. New onset LBBB was not associated with an increase in 1-year all-cause mortality (p=0.416). Factors that were associated with mortality included an increasing logistic EuroScore (p=0.05), history of previous balloon aortic valvuloplasty (p=0.001), renal impairment (p=0.003), previous myocardial infarction with pre-existing LBBB (p=0.028) and atrial fibrillation (p=0.039). Lower baseline peak and mean AV gradients were also associated with greater mortality at 1 year (p=0.001), likely reflecting underlying left ventricular dysfunction.
In the majority of patients, LVEF remained unchanged following TAVI. Interestingly, the presence or absence of new onset LBBB did not affect LVEF improvement at 30 days. 10% of patients required a PPM post TAVI. Predictors of PPM included new LBBB (OR 2.6, p<0.001), pre-TAVI left ventricular systolic impairment (OR 1.2, p=0.037), a self-expandable device (p<0.001), and pre-existing RBBB (OR 4.0, p<0.001).
Conclusions
These findings suggest that new onset LBBB post TAVI does not increase mortality at 1 year or adversely affect LVEF at 30 days.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- S.S Arri
- Guys and St Thomas Hospital, London, United Kingdom
| | - A Myat
- Royal Sussex County Hospital, Cardiology, Brighton, United Kingdom
| | - I Malik
- Imperial College London, Cardiology, London, United Kingdom
| | - N Curzen
- University Hospital Southampton NHS Foundation Trust, Cardiology, Southampton, United Kingdom
| | - A Baumbach
- University Hospitals Bristol NHS Foundation Trust, Cardiology, Bristol, United Kingdom
| | - M Gunning
- University Hospitals of North Midlands, Cardiology, Stoke-on-Trent, United Kingdom
| | - R Henderson
- Nottingham University Hospitals NHS Trust, Cardiology, Nottingham, United Kingdom
| | - P Ludman
- University Hospital Birmingham, Cardiology, Birmingham, United Kingdom
| | - A Banning
- Oxford University Hospitals NHS Foundation Trust, Cardiology, Oxford, United Kingdom
| | - D Blackman
- Leeds Teaching Hospitals NHS Trust, Cardiology, Leeds, United Kingdom
| | - C Densem
- Royal Papworth Hospital NHS Foundation Trust, Cardiology, Cambridge, United Kingdom
| | - R Stables
- Liverpool Heart and Chest Hospital, Cardiology, Liverpool, United Kingdom
| | - J Byrne
- King's College Hospital, Cardiology, London, United Kingdom
| | - D Hildick-Smith
- Royal Sussex County Hospital, Cardiology, Brighton, United Kingdom
| | - S.R Redwood
- Guys and St Thomas Hospital, London, United Kingdom
| |
Collapse
|
9
|
Beirne A, Rathod K, Jain A, Mathur A, Wragg A, Smith EJ, Jones DA, Kalra S, Malik I, Redwood S, MacCarthy P, Bogle R, Firoozi S, Dalby M. P6516The association between prior coronary artery bypass graft surgery and outcome after percutaneous coronary intervention (PCI): an observational study of 123,780 patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.1106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Limited information exists regarding procedural success and clinical outcomes in patients with previous CABG undergoing percutaneous coronary intervention (PCI). We sought to compare outcomes in patients undergoing PCI with or without previous coronary artery bypass grafts (CABG).
Methods
This was an observational cohort study of 123,780 consecutive PCI procedures from the Pan-London (United Kingdom) PCI registry, from January 2005 to December 2015. The primary end-point was all-cause mortality at a median follow-up of 3.0 years (interquartile range 1.2–4.6 years).
Results
12,641 (10.2%) patients had a history of previous CABG, of whom 29.3% (n=3,703) underwent PCI to native vessels and 70.7% (n=8,938) to bypass grafts. There were significant differences in the demographic, clinical, and procedural characteristics of these groups. The risk of mortality during follow-up was significantly higher in patients with prior CABG (23.2%) (p=0.0005) compared to patients with no history of prior CABG (12.1%) and was seen for patients who underwent either native vessel (20.1%) or bypass graft PCI (24.2%, p<0.0001). However, after adjustment for baseline characteristics, there was no significant difference in outcomes seen between the groups when PCI was performed in native vessels in patients with previous CABG (HR 1.02, 95% CI 0.77–1.34; P=0.89) but a significant increase in mortality among patients with PCI to bypass grafts (HR 1.33 95% CI 1.03–1.71, P=0.026). This was seen after multivariate adjustment and propensity matching.
Figure 1. Kaplan-Meier Curves
Conclusion
Patients with prior CABG are older, with a greater comorbid burden and more complex procedural characteristics, but after adjustment for these differences clinical outcomes are similar to patients undergoing PCI without prior CABG. In these patients, native vessel PCI was associated with better outcomes compared to the treatment of vein grafts.
Collapse
Affiliation(s)
- A Beirne
- Barts Health NHS Trust, London, United Kingdom
| | - K Rathod
- Barts Health NHS Trust, London, United Kingdom
| | - A Jain
- Barts Health NHS Trust, London, United Kingdom
| | - A Mathur
- Barts Health NHS Trust, London, United Kingdom
| | - A Wragg
- Barts Health NHS Trust, London, United Kingdom
| | - E J Smith
- Barts Health NHS Trust, London, United Kingdom
| | - D A Jones
- Barts Health NHS Trust, London, United Kingdom
| | - S Kalra
- Royal Free Hospital, London, United Kingdom
| | - I Malik
- Imperial College Healthcare NHS Trust, London, United Kingdom
| | - S Redwood
- St Thomas' Hospital, London, United Kingdom
| | - P MacCarthy
- Kings College Hospital, London, United Kingdom
| | - R Bogle
- St Georges Hospital, London, United Kingdom
| | - S Firoozi
- St Georges Hospital, London, United Kingdom
| | - M Dalby
- Harefield Hospital, London, United Kingdom
| |
Collapse
|
10
|
Bak A, Kozik V, Malik I, Jampilek J, Smolinski A. Probability-driven 3D pharmacophore mapping of antimycobacterial potential of hybrid molecules combining phenylcarbamoyloxy and N-arylpiperazine fragments. SAR QSAR Environ Res 2018; 29:801-821. [PMID: 30230355 DOI: 10.1080/1062936x.2018.1517278] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2018] [Accepted: 08/25/2018] [Indexed: 06/08/2023]
Abstract
The current study examines in silico characterization of the structure-inhibitory potency for a set of phenylcarbamic acid derivatives containing an N-arylpiperazine scaffold, considering the electronic, steric and lipophilic properties. The main objective of the ligand-based modelling was the systematic study of classical comparative molecular field analysis (CoMFA)/comparative molecular surface analysis (CoMSA) performance for the modelling of in vitro efficiency observed for these phenylcarbamates, revealing their inhibitory activities against a virulent Mycobacterium tuberculosis H37Rv strain. We compared the findings of efficiency modelling produced by a standard 3D methodology (CoMFA) and its neural counterparts (CoMSA) regarding multiple training/test subsets and variables used. Moreover, systematic space inspection, splitting values into the analysed training/test subsets, was performed to monitor statistical estimator performance while mapping the probability-driven pharmacophore pattern. Consequently, a 'pseudo-consensus' 3D-quantitative structure-activity relationship (3D-QSAR) approach was applied to retrieve an 'average' pharmacophore hypothesis by the investigation of the most densely populated training/test subpopulations to specify the potentially important factors contributing to the inhibitory activity of phenylcarbamic acid analogues. In addition, examination of descriptor-based similarity with a principal component analysis (PCA) procedure was employed to visualize noticeable variations in the performance of these molecules with respect to their structure and activity profiles.
Collapse
Affiliation(s)
- A Bak
- a Department of Synthesis Chemistry , Institute of Chemistry, University of Silesia , Katowice , Poland
| | - V Kozik
- a Department of Synthesis Chemistry , Institute of Chemistry, University of Silesia , Katowice , Poland
| | - I Malik
- b Department of Pharmaceutical Chemistry, Faculty of Pharmacy , Comenius University , Bratislava , Slovakia
| | - J Jampilek
- b Department of Pharmaceutical Chemistry, Faculty of Pharmacy , Comenius University , Bratislava , Slovakia
| | - A Smolinski
- c Department of Energy Saving and Air Protection , Central Mining Institute , Katowice , Poland
| |
Collapse
|
11
|
Ahmad Y, Howard J, Arnold A, Shun-Shin M, Cook C, Petraco R, Sutaria N, Malik I, Mayet J, Francis DP, Sen S. P716PFO closure is superior to medical therapy for cryptogenic stroke: a meta-analysis of randomised controlled trials. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Y Ahmad
- Imperial College London, London, United Kingdom
| | - J Howard
- Imperial College London, London, United Kingdom
| | - A Arnold
- Imperial College London, London, United Kingdom
| | - M Shun-Shin
- Imperial College London, London, United Kingdom
| | - C Cook
- Imperial College London, London, United Kingdom
| | - R Petraco
- Imperial College London, London, United Kingdom
| | - N Sutaria
- Imperial College NHS Healthcare Trust, Cardiolog, London, United Kingdom
| | - I Malik
- City Hospital Birmingham, University of Birmingham Centre for Cardiovascular Medicine, Birmingham, United Kingdom
| | - J Mayet
- Imperial College London, London, United Kingdom
| | - D P Francis
- Imperial College London, London, United Kingdom
| | - S Sen
- Imperial College London, London, United Kingdom
| |
Collapse
|
12
|
Sanusi T, Davis J, Nicassio N, Malik I. Endoscopic lumbar discectomy under local anesthesia may be an alternative to microdiscectomy: A single centre's experience using the far lateral approach. Clin Neurol Neurosurg 2015; 139:324-7. [PMID: 26583835 DOI: 10.1016/j.clineuro.2015.11.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2015] [Revised: 09/16/2015] [Accepted: 11/01/2015] [Indexed: 10/22/2022]
Abstract
OBJECTIVES Since the turn of the century, minimally invasive surgery has become increasingly widespread. Discectomy surgery has evolved from wide open to microscopic and now endoscopic. This study aims to demonstrate that transforaminal endoscopic discectomy is an alternative and safe approach for degenerative disk surgery. PATIENTS AND METHODS Two year retrospective assessments of patients who underwent transforaminal endoscopic discectomy at a tertiary neurosurgical center in the United Kingdom by a single surgeon. Under strict confidentiality, data was collected from online patient data and PACS systems. Patient feedback was achieved using phone call follow up and clinic appointments. Standard statistical analysis was performed. RESULTS 201 patients had endoscopic discectomy and the mean age was 41 years. Male:female ratio was 1.3:1.0. Mean time of onset of symptoms was 5.5 months and the most common level was L4/5 (53%). All endoscopic discectomies were performed under local anesthesia. Theater time was on average 110 min. 10 patients were lost to follow up. 95% of patients were discharged within 7h post operatively. Visual acuity score of the pain dropped from an average of 7/10 pre-operatively to 0-1/10 in 95% of patients two weeks post operatively. 87% patients went back to their normal daily activities within two weeks. There were no cases of CSF leak, hematoma formation or wound infection. 1% of patients developed a nerve root injury. 6% of patients had recurrent herniation and require microdiscectomy. CONCLUSION Endoscopic discectomy can be an alternative approach to microdiscectomy. While it can take more expertise to perform endoscopic discectomy, our data shows that the far lateral endoscopic discectomy using the TESSYS technique has comparable outcomes to microdiscectomy.
Collapse
Affiliation(s)
- T Sanusi
- Department of Neurosurgery, Kings College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
| | - J Davis
- Department of Neurosurgery, Kings College Hospital, Denmark Hill, London SE5 9RS, United Kingdom.
| | - N Nicassio
- Department of Neurosurgery, Kings College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
| | - I Malik
- Department of Neurosurgery, Kings College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
| |
Collapse
|
13
|
Higgins P, Malik I, Ghosh S. 33 * IMPROVED DOCUMENTATION OF DELIRIUM AND CAPACITY ASSESSMENTS IN THE MEDICAL RECEIVING UNIT. Age Ageing 2014. [DOI: 10.1093/ageing/afu124.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Tempe DK, Malik I. Why do we not toe the line drawn by the National Institute for Clinical Excellence for internal jugular vein cannulation? Br J Anaesth 2014; 113:344-5. [PMID: 24875661 DOI: 10.1093/bja/aeu146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- D K Tempe
- Department of Anaesthesiology and Intensive Care, Govind Ballabh Pant Hospital, Jawaharlal Nehru Road, New Delhi 110002, India Maulana Azad Medical College and Associated GB Pant, Loknayak and GNEC Hospitals, New Delhi, India
| | - I Malik
- Department of Anaesthesiology and Intensive Care, Govind Ballabh Pant Hospital, Jawaharlal Nehru Road, New Delhi 110002, India
| |
Collapse
|
15
|
Hussain M, Thai Hung N, Abbas N, Khera RA, Malik I, Patonay T, Kelzhanova N, Abilov ZA, Villinger A, Langer P. Synthesis of Arylated Benzofurans by RegioselectiveSuzuki-Miyaura Cross-Coupling Reactions of 2,3-Dibromobenzofurans- and 2,3,5-Tribromobenzofurans. J Heterocycl Chem 2014. [DOI: 10.1002/jhet.2083] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Hussain
- Institut für Chemie; Universität Rostock; Albert Einstein Street 3a 18059 Rostock Germany
| | - N. Thai Hung
- Institut für Chemie; Universität Rostock; Albert Einstein Street 3a 18059 Rostock Germany
| | - N. Abbas
- Institut für Chemie; Universität Rostock; Albert Einstein Street 3a 18059 Rostock Germany
- Department of Chemistry; University of Gujrat; Gujrat 50700 Pakistan
| | - R. A. Khera
- Institut für Chemie; Universität Rostock; Albert Einstein Street 3a 18059 Rostock Germany
- Department of Chemistry and Biochemistry; University of Agriculture; Faisalabad 38040 Pakistan
| | - I. Malik
- Institut für Chemie; Universität Rostock; Albert Einstein Street 3a 18059 Rostock Germany
- Department of Chemistry, COMSATS; Institute of Information Technology; Abbottabad 22060 Khyber Pakhtunkhwa Pakistan
| | - T. Patonay
- Department of Organic Chemistry; University of Debrecen; H-4032 Debrecen Egyetem tér 1 Hungary
| | - N. Kelzhanova
- Institut für Chemie; Universität Rostock; Albert Einstein Street 3a 18059 Rostock Germany
- Al-Farabi Kazakh National University; Al-Farabi ave. 71 050040 Almaty Kazakhstan
| | - Z. A. Abilov
- Al-Farabi Kazakh National University; Al-Farabi ave. 71 050040 Almaty Kazakhstan
| | - A. Villinger
- Institut für Chemie; Universität Rostock; Albert Einstein Street 3a 18059 Rostock Germany
| | - P. Langer
- Institut für Chemie; Universität Rostock; Albert Einstein Street 3a 18059 Rostock Germany
- Leibniz-Institut für Katalyse an der Universität Rostock e.V; Albert Einstein Street 29a 18059 Rostock Germany
| |
Collapse
|
16
|
Calvet D, Mas JL, Algra A, Becquemin JP, Bonati LH, Dobson J, Fraedrich G, Jansen O, Mali WP, Ringleb PA, Chatellier G, Brown MM, Calvet D, Mas JL, Algra A, Becquemin JP, Bonati L, Dobson J, Fraedrich G, Jansen O, Mali W, Ringleb P, Chatellier G, Brown M, Algra A, Becquemin J, Chatellier G, Mas JL, Fraedrich G, Ringleb P, Jansen O, Bonati LH, Brown MM, Mali WP, Mas JL, Chatellier G, Becquemin JP, Bonneville JF, Branchereau A, Crochet D, Gaux JC, Larrue V, Leys D, Watelet J, Hacke W, Hennerici M, Allenberg J, Maurer P, Eckstein HH, Zeumer H, Jansen O, Algra A, Bamford J, Beard J, Bland M, Bradbury A, Brown M, Clifton A, Gaines P, Hacke W, Halliday A, Malik I, Mas JL, McGuire A, Sidhu P, Venables G. Carotid Stenting. Stroke 2014; 45:527-32. [DOI: 10.1161/strokeaha.113.003526] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- David Calvet
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Jean-Louis Mas
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Ale Algra
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Jean-Pierre Becquemin
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Leo H. Bonati
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Joanna Dobson
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Gustav Fraedrich
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Olav Jansen
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Willem P. Mali
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Peter A. Ringleb
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Gilles Chatellier
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - Martin M. Brown
- From the Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France (D.C., J.-L.M.); Department of Neurology and Julius Centre for Health Sciences and Patient Care (A.A.) and Department of Radiology (W.P.M.), University Medical Centre Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, University Hospital Henri Mondor, Creteil, France (J.-P.B.); Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland (L.H.B.)
| | - D. Calvet
- Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France
| | - J.-L. Mas
- Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, INSERM UMR894, Paris, France
| | - A. Algra
- Department of Neurology and Julius Centre for Health Sciences and Patient Care, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - J.-P. Becquemin
- Department of Vascular Surgery, University Hospital Henri Mondor, 94010 Creteil, France
| | - L.H. Bonati
- Department of Neurology and Stroke Unit, University Hospital Basel, Basel, Switzerland; and Department of Brain Repair and Rehabilitation, Institute of Neurology, University College London, London, United Kingdom
| | - J. Dobson
- Medical Statistics Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - G. Fraedrich
- Department of Vascular Surgery, Medical University, Innsbruck, Austria
| | - O. Jansen
- Department of Neuroradiology, Schleswig-Holstein University Hospital, Kiel, Germany
| | - W.P. Mali
- Department of Radiology, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - P.A. Ringleb
- Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany
| | - G. Chatellier
- Clinical Research Unit, Hôpital Européen Georges Pompidou, Université René Descartes, Paris, France
| | - M.M. Brown
- Department of Brain Repair and Rehabilitation, Institute of Neurology, University College London, London, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Amanzada A, Malik I, Ramadori G, Moriconi F. Identification of CD68+ neutrophil granulocytes in in vitro model of acute inflammation and inflammatory bowel disease. Z Gastroenterol 2013. [DOI: 10.1055/s-0033-1352657] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Altman M, Bergerot C, Thibault H, Aussoleil A, Skuldadt Davidsen E, Barthelet M, Derumeaux GA, Grapsa J, Zimbarra Cabrita I, Afilalo J, Paschou S, Dawson D, Durighel G, O'regan D, Howard L, Gibbs J, Nihoyannopoulos P, Morenate Navio M, Mesa Rubio M, Ortega MD, Ruiz Ortiz M, Castillo Bernal F, Del Pino CL, Toledano F, Alvarez-Ossorio MP, Ojeda Pineda S, Lezo Cruz-Conde JSD, Jasaityte R, Claus P, Teske A, Herbots L, Verheyden B, Rademakers F, D'hooge J, Tocchetti CG, Coppola C, Rea D, Quintavalle C, Guarino L, Castaldo N, De Lorenzo C, Condorelli G, Arra C, Maurea N, Voilliot D, Huttin O, Camara Y, Djaballah W, Carillo S, Zinzius P, Sellal J, Angioi M, Juilliere Y, Selton-Suty C, Dobrowolski P, Klisiewicz A, Florczak E, Prejbisz A, Szwench E, Rybicka J, Januszewicz A, Hoffman P, Jurado Roman A, De Dios Perez S, De Nicolas JMM, Diaz Anton B, Rubio Alonso B, Martin Asenjo R, Mayordomo Gomez S, Villagraz Tecedor L, Blazquez L, De Meneses RT, Bernard A, Hernandez AI, Reynaud A, Lerclercq C, Daubert J, Donal E, Arjan Singh R, Sivarani S, Lim S, Azman W, Almeida M, Cardim N, Fonseca V, Carmelo V, Santos S, Santos T, Toste J, Kosmala W, Orda A, Karolko B, Mysiak A, Przewlocka-Kosmala M, Farsalinos K, Tsiapras D, Kyrzopoulos S, Avramidou E, Vassilopoulou D, Voudris V, Hayrapetyan H, Adamyan K, Jurado Roman A, De Dios Perez S, Rubio Alonso B, De Nicolas JMM, Diaz Anton B, Martin Asenjo R, Montero Cabezas J, Granda Nistal C, Garcia Aranda B, Sanchez Sanchez V, Sestito A, Lamendola P, Di Franco A, Lauria C, Lanza G, Kukucka M, Unbehaun A, Buz S, Mladenow A, Kuppe H, Pasic M, Habazettl H, Gemma D, Montoro Lopez N, De Celix MGR, Lopez Fernandez T, De Torres Alba F, Del Valle DI, Ramirez U, Mesa J, Moreno Yanguela M, Lopez Sendon J, Eveborn GW, Schirmer H, Lunde P, Heggelund G, Rasmussen K, Wang Z, Lasota B, Mizia-Stec K, Mizia M, Chmiel A, Adamczyk T, Chudek J, Gasior Z, Venkatesh A, Johnson J, Sahlen A, Brodin L, Winter R, Shahgaldi K, Manouras A, Valbuena S, Iniesta A, Lopez T, De Torres F, Salinas P, Garcia S, Ramirez U, Mesa J, Moreno M, Lopez-Sendon J, Lebid I, Kobets T, Kuzmenko T, Katsanos S, Yiu K, Clavel M, Nina Ajmone N, Van Der Kley F, Rodes Cabau J, Schalij M, Bax J, Pibarot P, Delgado V, Fusini L, Tamborini G, Muratori M, Gripari P, Marsan N, Cefalu' C, Ewe S, Maffessanti F, Delgado V, Pepi M, Hasselberg N, Haugaa K, Petri H, Berge K, Leren T, Bundgaard H, Edvardsen T, Ancona R, Comenale Pinto S, Caso P, Coppola M, Rapisarda O, Cavallaro C, Vecchione F, D'onofrio A, Calabro' R, Rimbas R, Mihaila S, Enescu O, Patrascu N, Dragoi R, Rimbas M, Pop C, Vinereanu D, Gustafsson S, Morner S, Gronlund C, Suhr O, Lindqvist P, Di Bella G, Zito C, Minutoli F, Madaffari A, Cusma Piccione M, Mazzeo A, Massimo R, Pasquale M, Vita G, Carerj S, Rangel I, Goncalves A, Sousa C, Correia A, Martins E, Silva-Cardoso J, Macedo F, Maciel M, Pfeiffer B, Rigopoulos A, Seggewiss H, Alvarez Fuente M, Sainz Costa T, Medrano C, Navarro M, Blazquez Gamero D, Ramos J, Mellado M, De Jose M, Munoz M, Maroto E, Gargani L, Gosciniak P, Pratali L, Agoston G, Bruni C, Guiducci S, Matucci Cerinic M, Varga A, Sicari R, Picano E, Yiu K, Zhao C, Mei M, Yeung C, Siu C, Tse H, Florescu M, Enescu O, Magda L, Mincu R, Vinereanu D, Daha I, Stanescu CM, Chirila L, Baicus C, Vlase A, Dan G, Montoro Lopez M, Florez Gomez R, Alonso Ladreda A, Itziar Soto C, Rios Blanco J, Gemma D, De Torres Alba F, Moreno Yanguela M, Lopez Sendon J, Guzman Martinez G, Lichodziejewska B, Kurnicka K, Goliszek S, Kostrubiec M, Dzikowska-Diduch O, Ciurzynski M, Labyk A, Krupa M, Palczewski P, Pruszczyk P, De Sousa CC, Rangel I, Correia A, Martins E, Vigario A, Pinho T, Silva Cardoso J, Goncalves A, Macedo F, Maciel M, Park SJ, Song JE, Lee YJ, Ha MR, Chang SA, Choi JO, Lee SC, Park S, Oh J, Van De Bruaene A, De Meester P, Buys R, Vanhees L, Delcroix M, Voigt J, Budts W, Blundo A, Buccheri S, Monte IP, Leggio S, Tamburino C, Sotaquira M, Fusini L, Maffessanti F, Pepi M, Lang R, Caiani E, Floria M, De Roy L, Xhaet O, Blommaert D, Jamart J, Gerard M, Deceuninck O, Marchandise B, Seldrum S, Schroeder E, Unsworth B, Sohaib S, Kulwant-Kaur K, Malcolme-Lawes L, Kanagaratnam P, Malik I, Ren B, Mulder H, Haak A, Van Stralen M, Szili-Torok T, Pluim J, Geleijnse M, Bosch J, Baglini R, Amaducci A, D'ancona G, Van Den Oord S, Akkus Z, Bosch J, Ten Kate G, Renaud G, Sijbrands E, De Jong N, Van Der Lugt A, Van Der Steen A, Schinkel A, Bjallmark A, Larsson M, Grishenkov D, Brodin LA, Brismar T, Paradossi G, Sveen KA, Nerdrum T, Hanssen K, Dahl-Jorgensen K, Steine K, Cimino S, Pedrizzetti G, Tonti G, Canali E, Petronilli V, Cicogna F, Arcari L, De Luca L, Iacoboni C, Agati L, Abdel Moneim SS, Eifert Rain S, Bernier M, Bhat G, Hagen M, Bott-Kitslaar D, Castello R, Wilansky S, Pellikka P, Mulvagh S, Delithanasis I, Celutkiene J, Kenny C, Monaghan M, Park W, Hong G, Son J, Lee S, Kim U, Park J, Shin D, Kim Y, Toutouzas K, Drakopoulou M, Aggeli C, Felekos I, Nikolaou C, Synetos A, Stathogiannis K, Tsiamis E, Siores E, Stefanadis C, Plicht B, Kahlert P, Grave T, Buck T, Konorza T, Gursoy M, Gokdeniz T, Astarcioglu M, Bayram Z, Cakal B, Karakoyun S, Kalcik M, Acar R, Kahveci G, Ozkan M, Maffessanti F, Tamborini G, Tsang W, Weinert L, Gripari P, Fusini L, Muratori M, Caiani E, Lang R, Pepi M, Yurdakul S, Avci B, Sahin S, Dilekci B, Aytekin S, Ancona R, Comenale Pinto S, Caso P, Arenga F, Coppola M, Rapisarda O, Calabro' R, Hascoet S, Martin R, Dulac Y, Peyre M, Benzouid C, Hadeed K, Acar P, Celutkiene J, Zakarkaite D, Skorniakov V, Zvironaite V, Grabauskiene V, Burca J, Ciparyte L, Laucevicius A, Di Salvo G, Rea A, D'aiello A, Del Gaizo F, Pergola V, D'andrea A, Caso P, Pacileo G, Calabro R, Russo M, Dedobbeleer C, Hadefi A, Naeije R, Unger P, Mornos C, Cozma D, Ionac A, Mornos A, Valcovici M, Pescariu S, Petrescu L, Hu K, Liu D, Niemann M, Herrmann S, Cikes M, Stoerk S, Knop S, Ertl G, Bijnens B, Weidemann F, De Knegt M, Biering-Sorensen T, Sogaard P, Sivertsen J, Jensen J, Mogelvang R, Dedobbeleer C, Hadefi A, Unger P, Naeije R, Lam W, Tang M, Chan K, Yang Y, Fang F, Sun J, Yu C, Lam Y, Panoulas V, Sulemane S, Bratsas A, Konstantinou K, Nihoyannopoulos P, Cimino S, Canali E, Petronilli V, Cicogna F, Arcari L, De Luca L, Francone M, Iacoboni C, Agati L, Schau T, Seifert M, Ridjab D, Schoep M, Gottwald M, Neuss M, Meyhoefer J, Zaenker M, Butter C, Tarr A, Stoebe S, Pfeiffer D, Hagendorff A, Maret E, Ahlander BM, Bjorklund PG, Engvall J, Staskiewicz G, Czekajska-Chehab E, Adamczyk P, Siek E, Przybylski P, Maciejewski R, Drop A, Jimenez Rubio C, Isasti Aizpurua G, Miralles Ibarra J, Al-Mallah M, Somg T, Alam S, Chattahi J, Zweig B, Dhanalakota K, Boedeker S, Ananthasubramaniam K, Park C, March K, Jones S, Mayet J, Tillin T, Chaturvedi N, Hughes A, Hamodraka E, Kallistratos E, Karamanou A, Tsoukas T, Mavropoulos D, Kouremenos N, Zaharopoulou I, Nikolaidis N, Kremastinos D, Manolis A, Loboz-Rudnicka M, Jaroch J, Bociaga Z, Kruszynska E, Ciecierzynska B, Dziuba M, Dudek K, Uchmanowicz I, Loboz-Grudzien K, Silva D, Magalhaes A, Jorge C, Cortez-Dias N, Carrilho-Ferreira P, Silva Marques J, Portela I, Pascoa C, Nunes Diogo A, Brito D, Roosens B, Bala G, Droogmans S, Hostens J, Somja J, Delvenne E, Schiettecatte J, Lahoutte T, Van Camp G, Cosyns B. Poster Session: Right ventricular systolic function. Eur Heart J Cardiovasc Imaging 2012. [DOI: 10.1093/ehjci/jes268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Sen S, Escaned J, Malik I, Mikhail G, Foale R, Mila R, Tarkin J, Petraco R, Broyd C, Jabbour R, Sethi A, Baker C, Bellamy M, Al-Bustami M, Hackett D, Khan M, Lefroy D, Parker K, Hughes A, Francis D, Di Mario C, Mayet J, Davies J. 019 Development and validation of a novel pressure-only intra-coronary index of coronary stenosis severity. Heart 2012. [DOI: 10.1136/heartjnl-2012-301877b.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
20
|
Engelien E, Malik I, Viga R, Kokozinski R. Flow Sensor for the Velocity Measurement at a Pulsed Volume Flow. BIOMED ENG-BIOMED TE 2012. [DOI: 10.1515/bmt-2012-4216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
Savage MW, Malik I, Dang CN. The case for basal analogue insulins as first-line insulins: back to the future? Practical Diabetes 2011. [DOI: 10.1002/pdi.1628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
22
|
Abbas S, Damani S, Malik I, Button E, Aldridge S, Palmer RL. A comparative study of South Asian and non-Asian referrals to an eating disorders service in Leicester, UK. Eur Eat Disorders Rev 2010; 18:404-9. [PMID: 20593482 DOI: 10.1002/erv.1033] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S Abbas
- Eating Disorders Service, Brandon Mental Health Unit, Leicester General Hospital, Leicestershire Partnership Trust, Leicester, UK
| | | | | | | | | | | |
Collapse
|
23
|
Hadjiloizou N, Davies J, Baksi J, Malik I, Hughes A, Foale R, Parker K, Francis D, Mayet J. 098 Differential effects of hypertrophy secondary to hypertension and aortic stenosis on coronary haemodynamics. Heart 2010. [DOI: 10.1136/hrt.2010.196071.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
24
|
Unsworth B, Malik I, Mikhail GW. Recognising bicuspid aortic stenosis in patients referred for transcatheter aortic valve implantation: routine screening with three-dimensional transoesophageal echocardiography. Heart 2010; 96:645. [DOI: 10.1136/hrt.2009.177659] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
25
|
|
26
|
Van Herzeele I, Aggarwal R, Malik I, Gaines P, Hamady M, Darzi A, Cheshire N, Vermassen F. Validation of Video-based Skill Assessment in Carotid Artery Stenting. Eur J Vasc Endovasc Surg 2009; 38:1-9. [DOI: 10.1016/j.ejvs.2009.03.008] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2008] [Accepted: 03/16/2009] [Indexed: 10/20/2022]
|
27
|
Hecht JR, Pillai M, Gollard R, Dreiling L, Mo M, Malik I. Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase II, randomized, controlled study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4072 Background: Survival in advanced CRC is prolonged by adding oxaliplatin (Ox) and/or irinotecan (Iri) to Q2W 5-fluorouracil/leucovorin (5FU/LV). Combination therapy, however, has a higher incidence of febrile neutropenia (FN) and related toxicities. This study evaluated pegfilgrastim dosing on day 4 of Q2W regimens in CRC. Here we present long-term follow-up of these pts. Methods: Advanced CRC pts were randomized (1:1) to pegfilgrastim 6mg or placebo, which was stratified by CT regimen received: FOIL, FOLFOX, or FOLFIRI. We previously reported grade 3/4 neutropenia (primary endpoint) in 43% placebo and 13% pegfilgrastim pts in the 4-cycle treatment phase (odds ratio = 0.19, 95% CI: 0.10–0.37; p < 0.0001). After end of treatment, pts were followed long term for ≤ 2 years (inclusive of ≤ 8 additional cycles) for serious adverse events (SAEs), overall survival (OS), and progression-free survival (PFS). Median follow-up time was 519 days. Kaplan-Meier methods estimated OS and PFS from study day 1. The study was not powered to detect PFS or OS differences between treatment groups. Results: Of 241 pts analyzed (123 pegfilgrastim, 118 placebo), 49% received FOLFOX, 26% FOLFIRI, and 25% FOIL. In the treatment period, 8% placebo and 2% pegfilgrastim pts had grade 3/4 FN ( Table ). Pegfilgrastim was well tolerated with no dose delays attributed to leukocytosis. Pegfilgrastim and placebo had similar PFS and OS ( Table ). No SAEs related to study drug were reported in the follow-up period. Conclusions: In this randomized, placebo-controlled study, pegfilgrastim significantly lowered neutropenic risk. Bone pain incidence in this CRC population was lower than in breast cancer pts treated with a taxane (Vogel J Clin Oncol 2005); the incidence in pegfilgrastim pts was modestly increased over placebo. Leukocytosis was not a concern despite the 11-day dosing interval. Long-term results suggest similar PFS and OS in the pegfilgrastim and placebo pts in this CRC study. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- J. R. Hecht
- University of California at Los Angeles, Los Angeles, CA; Virginia Oncology Care, Richlands, VA; Cancer and Blood Specialists of Nevada, Henderson, NV; Amgen, Inc., Thousand Oaks, CA; Loma Linda Oncology Medical Group, Claremont, CA
| | - M. Pillai
- University of California at Los Angeles, Los Angeles, CA; Virginia Oncology Care, Richlands, VA; Cancer and Blood Specialists of Nevada, Henderson, NV; Amgen, Inc., Thousand Oaks, CA; Loma Linda Oncology Medical Group, Claremont, CA
| | - R. Gollard
- University of California at Los Angeles, Los Angeles, CA; Virginia Oncology Care, Richlands, VA; Cancer and Blood Specialists of Nevada, Henderson, NV; Amgen, Inc., Thousand Oaks, CA; Loma Linda Oncology Medical Group, Claremont, CA
| | - L. Dreiling
- University of California at Los Angeles, Los Angeles, CA; Virginia Oncology Care, Richlands, VA; Cancer and Blood Specialists of Nevada, Henderson, NV; Amgen, Inc., Thousand Oaks, CA; Loma Linda Oncology Medical Group, Claremont, CA
| | - M. Mo
- University of California at Los Angeles, Los Angeles, CA; Virginia Oncology Care, Richlands, VA; Cancer and Blood Specialists of Nevada, Henderson, NV; Amgen, Inc., Thousand Oaks, CA; Loma Linda Oncology Medical Group, Claremont, CA
| | - I. Malik
- University of California at Los Angeles, Los Angeles, CA; Virginia Oncology Care, Richlands, VA; Cancer and Blood Specialists of Nevada, Henderson, NV; Amgen, Inc., Thousand Oaks, CA; Loma Linda Oncology Medical Group, Claremont, CA
| |
Collapse
|
28
|
Gregory A, Westaway SK, Holm IE, Kotzbauer PT, Hogarth P, Sonek S, Coryell JC, Nguyen TM, Nardocci N, Zorzi G, Rodriguez D, Desguerre I, Bertini E, Simonati A, Levinson B, Dias C, Barbot C, Carrilho I, Santos M, Malik I, Gitschier J, Hayflick SJ. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008; 71:1402-9. [PMID: 18799783 DOI: 10.1212/01.wnl.0000327094.67726.28] [Citation(s) in RCA: 205] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE Mutations in the gene encoding phospholipase A(2) group VI (PLA2G6) are associated with two childhood neurologic disorders: infantile neuroaxonal dystrophy (INAD) and idiopathic neurodegeneration with brain iron accumulation (NBIA). INAD is a severe progressive psychomotor disorder in which axonal spheroids are found in brain, spinal cord, and peripheral nerves. High globus pallidus iron is an inconsistent feature of INAD; however, it is a diagnostic criterion of NBIA, which describes a clinically and genetically heterogeneous group of disorders that share this hallmark feature. We sought to delineate the clinical, radiographic, pathologic, and genetic features of disease resulting from defective phospholipase A(2). METHODS We identified 56 patients clinically diagnosed with INAD and 23 with idiopathic NBIA and screened their DNA for PLA2G6 mutations. RESULTS Eighty percent of patients with INAD had mutations in PLA2G6, whereas mutations were found in only 20% of those with idiopathic NBIA. All patients with two null mutations had a more severe phenotype. On MRI, nearly all mutation-positive patients had cerebellar atrophy, and half showed brain iron accumulation. We observed Lewy bodies and neurofibrillary tangles in association with PLA2G6 mutations. CONCLUSION Defects in phospholipase A(2) lead to a range of phenotypes. PLA2G6 mutations are associated with nearly all cases of classic infantile neuroaxonal dystrophy but a minority of cases of idiopathic neurodegeneration with brain iron accumulation, and genotype correlates with phenotype. Cerebellar atrophy predicts which patients are likely to be mutation-positive. The neuropathologic changes that are caused by defective phospholipase A(2) suggest a shared pathogenesis with both Parkinson and Alzheimer diseases.
Collapse
Affiliation(s)
- A Gregory
- Department of Molecular and Medical Genetics, Oregon Health & Science University, L103a, 3181 SW Sam Jackson Park Rd., Portland, OR 97239-3098, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
|
30
|
|
31
|
Ramadori G, Moriconi F, Malik I, Dudas J. Physiology and pathophysiology of liver inflammation, damage and repair. J Physiol Pharmacol 2008; 59 Suppl 1:107-117. [PMID: 18802219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 07/11/2008] [Accepted: 07/23/2008] [Indexed: 05/26/2023]
Abstract
The liver is the largest organ of the body. It is located between the portal and the general circulation, between the organs of the gastrointestinal tract and the heart. The main function of the liver is to take up nutrients, to store them, and to provide nutrients to the other organs. At the same time has the liver to take up potentially damaging substances like bacterial products or drugs delivered by the portal blood or microorganisms, which reach the circulation. The liver is not only an important power and sewage treatment plant of the body. In fact, the liver is probably the best example for a cheap recycling system. Both parenchymal and nonparenchymal liver cells participate in the clearance activities. The function of the liver as clearance organ, however, harbors the danger that the substances that should be degraded and/or eliminated lead to tissue damage. Thus, effective defense mechanisms are necessary. Among the nonparenchymal cells Kupffer cells, sinusoidal endothelial cells, and natural killer (NK) lymphocytes exert cellular defense functions for the whole body but also for the liver itself. Furthermore, each cell type of the liver, including the hepatocytes, possesses its own defense apparatus.
Collapse
Affiliation(s)
- G Ramadori
- Department of Internal Medicine, Section of Gastroenterology and Endocrinology, Georg-August-University Goettingen, Goettingen, Germany.
| | | | | | | |
Collapse
|
32
|
|
33
|
Mitchell EP, Hecht JR, Baranda J, Malik I, Richards D, Reiner M, Stout S, Amado RG. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4082] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4082 Background: Panitumumab, a fully human monoclonal antibody against EGFr, is approved for EGFr-expressing mCRC pts with disease progression (PD) on or after fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. However, the predictive value of EGFr tumor-membrane staining as measured by immunohistochemistry (IHC) is undetermined. Methods: This multicenter, single arm, phase 2 study enrolled pts with documented PD during or after fluoropyrimidine and adequate doses of irinotecan and oxaliplatin, and within 6 months after the most recent chemotherapy regimen (determined by an independent eligibility review committee [IERC]), 2–3 prior regimens, and low (1%-9%) or negative (<1%) EGFr tumor membrane staining (by IHC). Pts received panitumumab 6mg/kg Q2W until PD or intolerability. Tumor assessments (modified WHO, blinded central review) were performed every 8 weeks until PD or discontinuation. Endpoints were objective response rate (ORR) through wk 16 (+ =4 wk confirmation; primary), overall ORR, response duration, progression-free survival (PFS), and safety (secondary). Results: In this interim analysis, 91 pts had =20 wks of potential follow-up and comprised the IERC efficacy set; 118 pts comprised the evaluable safety set (=20 wks potential follow-up). In the IERC efficacy set, 57% were male, 86% were white, and median age (range) was 61 (26–85) years. ORR through week 16 is shown; overall ORR was the same ( Table ). The most common adverse events (all, grade 3/4) were dermatitis acneiform (72%, 6%), erythema (69%, 6%), pruritus (65%, 4%), and hypomagnesaemia by lab values (53%, 10%). Four pts (3%) had an infusion reaction per investigator (1 was grade 3). Conclusions: This analysis confirms earlier findings that panitumumab has anti-tumor activity in pts with low or undetectable EGFr tumor membrane levels as measured by IHC. This study has completed enrollment, and updated data will be presented. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. P. Mitchell
- Thomas Jefferson University, Philadelphia, PA; UCLA School of Medicine, Los Angeles, CA; VA Medical Center, Kansas City, MO; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen Inc, Thousand Oaks, CA
| | - J. R. Hecht
- Thomas Jefferson University, Philadelphia, PA; UCLA School of Medicine, Los Angeles, CA; VA Medical Center, Kansas City, MO; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen Inc, Thousand Oaks, CA
| | - J. Baranda
- Thomas Jefferson University, Philadelphia, PA; UCLA School of Medicine, Los Angeles, CA; VA Medical Center, Kansas City, MO; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen Inc, Thousand Oaks, CA
| | - I. Malik
- Thomas Jefferson University, Philadelphia, PA; UCLA School of Medicine, Los Angeles, CA; VA Medical Center, Kansas City, MO; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen Inc, Thousand Oaks, CA
| | - D. Richards
- Thomas Jefferson University, Philadelphia, PA; UCLA School of Medicine, Los Angeles, CA; VA Medical Center, Kansas City, MO; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen Inc, Thousand Oaks, CA
| | - M. Reiner
- Thomas Jefferson University, Philadelphia, PA; UCLA School of Medicine, Los Angeles, CA; VA Medical Center, Kansas City, MO; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen Inc, Thousand Oaks, CA
| | - S. Stout
- Thomas Jefferson University, Philadelphia, PA; UCLA School of Medicine, Los Angeles, CA; VA Medical Center, Kansas City, MO; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen Inc, Thousand Oaks, CA
| | - R. G. Amado
- Thomas Jefferson University, Philadelphia, PA; UCLA School of Medicine, Los Angeles, CA; VA Medical Center, Kansas City, MO; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen Inc, Thousand Oaks, CA
| |
Collapse
|
34
|
Shevtsova Z, Malik I, Garrido M, Schöll U, Bähr M, Kügler S. Potentiation of in vivo neuroprotection by BclXL and GDNF co-expression depends on post-lesion time in deafferentiated CNS neurons. Gene Ther 2006; 13:1569-78. [PMID: 16838029 DOI: 10.1038/sj.gt.3302822] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
To elucidate effective and long-lasting neuroprotective strategies, we analysed a combination of mitochondrial protection and neurotrophic support in two well-defined animal models of neurodegeneration, traumatic lesion of optic nerve and complete 6-hydroxydopamine (6-OHDA) lesion of nigrostriatal pathway. Neuroprotection by BclX(L), Glial cell line-derived neurotrophic factor (GDNF) or BclX(L) plus GDNF co-expression were studied at 2 weeks and at 6-8 weeks after lesions. In both lesion paradigms, the efficacy of this combination approach significantly differed depending on post-lesion time. We show that BclX(L) expression is more important for neuronal survival in the early phase after lesions, whereas GDNF-mediated neuroprotection becomes more prominent in the advanced state of neurodegeneration. BclX(L) expression was not sufficient to finally inhibit degeneration of deafferentiated central nervous system neurons. Long-lasting GDNF-mediated neuroprotection depended on BclX(L) co-expression in the traumatic lesion paradigm, but was independent of BclX(L) in the 6-OHDA lesion model. The results demonstrate that neuroprotection studies in animal models of neurodegenerative diseases should generally be performed over extended periods of time in order to reveal the actual potency of a therapeutic approach.
Collapse
Affiliation(s)
- Z Shevtsova
- Department of Neurology, Medical School, University of Göttingen, Göttingen, Germany
| | | | | | | | | | | |
Collapse
|
35
|
Hecht J, Mitchell E, Baranda J, Malik I, Richards D, Navale L, D’Avirro P, Amado R. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3547] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3547 Background: Panitumumab is a fully human monoclonal antibody directed against EGFr. We investigated the antitumor activity of panitumumab in pts with mCRC who failed prior therapy and had low or negative EGFr tumor expression. Methods: In this multicenter, phase 2 study of 150 planned pts, pts had documentation of disease progression (PD) during or after adequate doses of fluoropyrimidine, irinotecan, and oxaliplatin (centrally confirmed refractory disease [CCRD]), 2–3 prior regimens, ECOG score 0–2, and low or negative EGFr staining (by IHC) in evaluable tumor cells. Pts received panitumumab at 6 mg/kg Q2W until PD or drug intolerability. Tumor assessments (modified WHO, blinded central review) were taken periodically from wk 8 until PD. Endpoints were objective response (OR) through wk 16 (+ ≥ 4 wk confirmation; primary) and OR throughout study, response duration, progression-free survival (PFS) time, survival time, and safety (secondary). Results: In this interim analysis (6/05), 88 pts were enrolled and had ≥ 1 dose of panitumumab (safety set); 23 pts had ≥ 20 wks before the cutoff and CCRD (efficacy set). The efficacy set consisted of 16M/7W, median age of 65 (range: 46, 85) yrs, 83% white, 100% with ECOG ≤ 1, 74% colon cancer and 26% rectal cancer; all received ≥ 2 prior regimens (equivalent characteristics for safety set). 2/11 (18%) pts with EGFr-negative tumors and 1/12 (8%) with low EGFr staining had a partial response. Duration was up to 16 wks. 7/23 (30%) of all pts had SD. Median (95% CI) PFS was 7.9 (7.0, 23.0) wks. In the safety set, all pts had a treatment-related adverse event; 19% grade (gr) 3; 2% gr 4. Integument and eye toxicities were: 92% skin, 17% eye, 28% nail, 8% hair, and 2% chelitis. 20 (23%) had diarrhea (1 gr 3); 7 (8%) had hypomagnesemia (2 gr 3/4). Three pts had an infusion reaction-1 gr 3 (led to panitumumab discontinuation) and 2 gr 1/2. In 65 pts with both a baseline and post-baseline sample, no human anti-human antibodies to panitumumab were detected. Updated data will be presented. Conclusions: Responses to panitumumab were seen in pts with mCRC with both low and negative EGFr levels. Efficacy appears similar to that in other studies with panitumumab in pts with higher EGFr tumor levels. [Table: see text]
Collapse
Affiliation(s)
- J. Hecht
- UCLA School of Medicine, Los Angeles, CA; Thomas Jefferson Medical College, Philadelphia, PA; University of Kansas Medical Center, Kansas City, KS; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen, Inc., Thousand Oaks, CA
| | - E. Mitchell
- UCLA School of Medicine, Los Angeles, CA; Thomas Jefferson Medical College, Philadelphia, PA; University of Kansas Medical Center, Kansas City, KS; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen, Inc., Thousand Oaks, CA
| | - J. Baranda
- UCLA School of Medicine, Los Angeles, CA; Thomas Jefferson Medical College, Philadelphia, PA; University of Kansas Medical Center, Kansas City, KS; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen, Inc., Thousand Oaks, CA
| | - I. Malik
- UCLA School of Medicine, Los Angeles, CA; Thomas Jefferson Medical College, Philadelphia, PA; University of Kansas Medical Center, Kansas City, KS; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen, Inc., Thousand Oaks, CA
| | - D. Richards
- UCLA School of Medicine, Los Angeles, CA; Thomas Jefferson Medical College, Philadelphia, PA; University of Kansas Medical Center, Kansas City, KS; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen, Inc., Thousand Oaks, CA
| | - L. Navale
- UCLA School of Medicine, Los Angeles, CA; Thomas Jefferson Medical College, Philadelphia, PA; University of Kansas Medical Center, Kansas City, KS; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen, Inc., Thousand Oaks, CA
| | - P. D’Avirro
- UCLA School of Medicine, Los Angeles, CA; Thomas Jefferson Medical College, Philadelphia, PA; University of Kansas Medical Center, Kansas City, KS; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen, Inc., Thousand Oaks, CA
| | - R. Amado
- UCLA School of Medicine, Los Angeles, CA; Thomas Jefferson Medical College, Philadelphia, PA; University of Kansas Medical Center, Kansas City, KS; Loma Linda Cancer Center, Loma Linda, CA; Tyler Cancer Center, Tyler, TX; Amgen, Inc., Thousand Oaks, CA
| |
Collapse
|
36
|
Tillin T, Dhutia H, Chambers J, Malik I, Coady E, Mayet J, Wright A, Kooner J, Chaturvedi N, Hughes A. Mo-P1:155 Southh Asians have narrower coronary arteries and different remodelling responses to disease compared to white Europeans. ATHEROSCLEROSIS SUPP 2006. [DOI: 10.1016/s1567-5688(06)80289-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
37
|
Tillin T, Dhutia H, Chambers J, Malik I, Coady E, Mayet J, Wright A, Kooner J, Chaturvedi N, Hughes A. Mo-P1:156 British South Asian men have more adverse plaque morphology despite equivalent atherosclerotic burden to white Europeans. ATHEROSCLEROSIS SUPP 2006. [DOI: 10.1016/s1567-5688(06)80290-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
38
|
Malik I, Hecht JR, Patnaik A, Venook A, Berlin J, Croghan G, Navale L, MacDonald M, Jerian S, Meropol NJ. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3520] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- I. Malik
- Loma Linda Univ Cancer Institute, Loma Linda, CA; UCLA Sch of Medicine, Los Angeles, CA; Cancer Therapy & Research Ctr, San Antonio, TX; Univ of CA San Francisco, San Francisco, CA; Vanderbilt Univ Medcl Ctr, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Ctr, Philadelphia, PA
| | - J. R. Hecht
- Loma Linda Univ Cancer Institute, Loma Linda, CA; UCLA Sch of Medicine, Los Angeles, CA; Cancer Therapy & Research Ctr, San Antonio, TX; Univ of CA San Francisco, San Francisco, CA; Vanderbilt Univ Medcl Ctr, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Ctr, Philadelphia, PA
| | - A. Patnaik
- Loma Linda Univ Cancer Institute, Loma Linda, CA; UCLA Sch of Medicine, Los Angeles, CA; Cancer Therapy & Research Ctr, San Antonio, TX; Univ of CA San Francisco, San Francisco, CA; Vanderbilt Univ Medcl Ctr, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Ctr, Philadelphia, PA
| | - A. Venook
- Loma Linda Univ Cancer Institute, Loma Linda, CA; UCLA Sch of Medicine, Los Angeles, CA; Cancer Therapy & Research Ctr, San Antonio, TX; Univ of CA San Francisco, San Francisco, CA; Vanderbilt Univ Medcl Ctr, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Ctr, Philadelphia, PA
| | - J. Berlin
- Loma Linda Univ Cancer Institute, Loma Linda, CA; UCLA Sch of Medicine, Los Angeles, CA; Cancer Therapy & Research Ctr, San Antonio, TX; Univ of CA San Francisco, San Francisco, CA; Vanderbilt Univ Medcl Ctr, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Ctr, Philadelphia, PA
| | - G. Croghan
- Loma Linda Univ Cancer Institute, Loma Linda, CA; UCLA Sch of Medicine, Los Angeles, CA; Cancer Therapy & Research Ctr, San Antonio, TX; Univ of CA San Francisco, San Francisco, CA; Vanderbilt Univ Medcl Ctr, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Ctr, Philadelphia, PA
| | - L. Navale
- Loma Linda Univ Cancer Institute, Loma Linda, CA; UCLA Sch of Medicine, Los Angeles, CA; Cancer Therapy & Research Ctr, San Antonio, TX; Univ of CA San Francisco, San Francisco, CA; Vanderbilt Univ Medcl Ctr, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Ctr, Philadelphia, PA
| | - M. MacDonald
- Loma Linda Univ Cancer Institute, Loma Linda, CA; UCLA Sch of Medicine, Los Angeles, CA; Cancer Therapy & Research Ctr, San Antonio, TX; Univ of CA San Francisco, San Francisco, CA; Vanderbilt Univ Medcl Ctr, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Ctr, Philadelphia, PA
| | - S. Jerian
- Loma Linda Univ Cancer Institute, Loma Linda, CA; UCLA Sch of Medicine, Los Angeles, CA; Cancer Therapy & Research Ctr, San Antonio, TX; Univ of CA San Francisco, San Francisco, CA; Vanderbilt Univ Medcl Ctr, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Ctr, Philadelphia, PA
| | - N. J. Meropol
- Loma Linda Univ Cancer Institute, Loma Linda, CA; UCLA Sch of Medicine, Los Angeles, CA; Cancer Therapy & Research Ctr, San Antonio, TX; Univ of CA San Francisco, San Francisco, CA; Vanderbilt Univ Medcl Ctr, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Ctr, Philadelphia, PA
| |
Collapse
|
39
|
Rajaraman C, Rowe JG, Walton L, Malik I, Radatz M, Kemeny AA. Treatment options for von Hippel-Lindau's haemangioblastomatosis: the role of gamma knife stereotactic radiosurgery. Br J Neurosurg 2005; 18:338-42. [PMID: 15702831 DOI: 10.1080/02688690400004944] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Haemangioblastomas secondary to von Hippel-Lindau (VHL) disease can be difficult to manage surgically, which has lead to an interest in the use of stereotactic radiosurgery. Retrospectively reviewed here are 30 tumours treated in 14 patients with a mean +/- SD follow-up of 34 +/- 24 months. During this time, three of the 14 patients (21%) died, two of generalized progressive disease. Before radiosurgery, the median time between interventions for cranial haemangioblastomas was 3 years (mean 3.9 +/- 5.0 years). After radiosurgery, the tendency for cranial disease progression was similar, 50% of patients developing further disease by 5 years. Local tumour control was achieved in the majority of cases and estimates of this are included. Radiosurgery is a useful palliative measure controlling the majority of haemangioblastomas, although its efficacy in these patients is limited by the tendency of further disease to develop or progress intracranially.
Collapse
Affiliation(s)
- C Rajaraman
- National Centre for Stereotactic Radiosurgery, Royal Hallamshire Hospital, Sheffield, UK
| | | | | | | | | | | |
Collapse
|
40
|
Hecht JR, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3511] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. R. Hecht
- UCLA School of Medicine, Los Angeles, CA; Cancer Therapy and Research Center, San Antonio, TX; Loma Linda University Cancer Institute, Loma Linda, CA; University of California San Francisco, San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - A. Patnaik
- UCLA School of Medicine, Los Angeles, CA; Cancer Therapy and Research Center, San Antonio, TX; Loma Linda University Cancer Institute, Loma Linda, CA; University of California San Francisco, San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - I. Malik
- UCLA School of Medicine, Los Angeles, CA; Cancer Therapy and Research Center, San Antonio, TX; Loma Linda University Cancer Institute, Loma Linda, CA; University of California San Francisco, San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - A. Venook
- UCLA School of Medicine, Los Angeles, CA; Cancer Therapy and Research Center, San Antonio, TX; Loma Linda University Cancer Institute, Loma Linda, CA; University of California San Francisco, San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - J. Berlin
- UCLA School of Medicine, Los Angeles, CA; Cancer Therapy and Research Center, San Antonio, TX; Loma Linda University Cancer Institute, Loma Linda, CA; University of California San Francisco, San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - G. Croghan
- UCLA School of Medicine, Los Angeles, CA; Cancer Therapy and Research Center, San Antonio, TX; Loma Linda University Cancer Institute, Loma Linda, CA; University of California San Francisco, San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - B. L. Wiens
- UCLA School of Medicine, Los Angeles, CA; Cancer Therapy and Research Center, San Antonio, TX; Loma Linda University Cancer Institute, Loma Linda, CA; University of California San Francisco, San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - S. Visonneau
- UCLA School of Medicine, Los Angeles, CA; Cancer Therapy and Research Center, San Antonio, TX; Loma Linda University Cancer Institute, Loma Linda, CA; University of California San Francisco, San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - S. Jerian
- UCLA School of Medicine, Los Angeles, CA; Cancer Therapy and Research Center, San Antonio, TX; Loma Linda University Cancer Institute, Loma Linda, CA; University of California San Francisco, San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Center, Philadelphia, PA
| | - N. J. Meropol
- UCLA School of Medicine, Los Angeles, CA; Cancer Therapy and Research Center, San Antonio, TX; Loma Linda University Cancer Institute, Loma Linda, CA; University of California San Francisco, San Francisco, CA; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MN; Amgen Inc., Thousand Oaks, CA; Fox Chase Cancer Center, Philadelphia, PA
| |
Collapse
|
41
|
Day J, Malik I, Weerasinghe A, Nadra I, Haskard D, Taylor K, Landis C. W01.16 Distinct yet complimentary roles of IIbIIIa inhibitors and heparin during platelet activation: Implications for restenosis following PCI. ATHEROSCLEROSIS SUPP 2004. [DOI: 10.1016/s1567-5688(04)90016-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
42
|
Malik I. JournalScan. Heart 2004. [DOI: 10.1136/heart.90.1.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
43
|
|
44
|
|
45
|
|
46
|
|
47
|
Malik I. JournalScan. Heart 2003. [DOI: 10.1136/heart.89.8.959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
48
|
Malik I. JournalScan. Heart 2003. [DOI: 10.1136/heart.89.7.815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
49
|
Malik I. JournalScan. Heart 2003. [DOI: 10.1136/heart.89.6.695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
50
|
Malik I. JournalScan. Heart 2003. [DOI: 10.1136/heart.89.5.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|